Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMHOTEP
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
- NCT04795661 ↗
- Active, not recruiting
- Centre Leon Berard
- Deep
We haven't built an HCP commentary report on IMHOTEP (pembrolizumab in localized resectable MSI/dMMR tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMHOTEP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 28 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Localized Resectable Tumor; MSI/dMMR
- Interventions
- Pembrolizumab
- Arms
- Cohort Colorectal cancer (CRC) · Experimental
- Cohort Oesogastric cancer · Experimental
- Cohort Other cancer · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Rate of complete pathological response (pCR) after surgery
- Sponsor
- Centre Leon Berard
- Start
- Oct 18, 2021
- Primary completion
- Oct 5, 2023
- Results posted
- No
- Registry record
- NCT04795661 · updated Sep 10, 2026
Publications
linked from the registry- de la Fouchardiere C, Zaanan A, de Montfort A, Cohen R, Le Sourd S, Tougeron D, Soularue E, Dubreuil O, Williet N, Samalin-Scalzi E, Piessen G, Hautefeuille V, Jary M, Ben Abdelghani M, Evesque L, Rochigneux P, Blanc E, Perol D, Bibeau F, Coutzac C. Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP. J Clin Oncol. 2026 Jun;44(16):1520-1528. doi: 10.1200/JCO-25-02169. Epub 2026 Apr 14. PubMed 41980235
- Klute KA, Shah MA. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257044. doi: 10.6004/jnccn.2025.7044. PubMed 40340830